Literature DB >> 18432832

Measurement of cytotoxic activity of NK/LAK cells.

T L Whiteside1.   

Abstract

In this unit, methodology is presented for measuring the capacity of human natural killer (NK) or lymphokine-activated killer (LAK) cells to lyse tumor cell targets. Cytotoxicity of these effector cells is evaluated in a short-term (51)Cr-release assay using NK-sensitive tumor cells as the targets for NK cells or NK-resistant tumor cells as the targets for LAK cells. In the basic protocol, a generic (51)Cr-release assay is described in which PBMC, purified NK cells or interleukin 2 (IL-2)-activated lymphocyte populations (LAK cells) are utilized as effector cells. Support protocols describe preparation of nonadherent tumor cells, cells obtained from malignant effusions, trypsinized tumor cells from adherent monolayer culture, or freshly isolated tumor cells from surgical specimens. All of these cell types can serve as the (51)Cr-labeled target cells in the basic protocol. The procedure for labeling target cells from any of these sources with (51)Cr is also provided.

Entities:  

Mesh:

Year:  2001        PMID: 18432832     DOI: 10.1002/0471142735.im0718s35

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  7 in total

1.  Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Authors:  Douglas B Johnson; Mellissa J Nixon; Yu Wang; Daniel Y Wang; Emily Castellanos; Monica V Estrada; Paula I Ericsson-Gonzalez; Candace H Cote; Roberto Salgado; Violeta Sanchez; Phillip T Dean; Susan R Opalenik; Daniel M Schreeder; David L Rimm; Ju Young Kim; Jennifer Bordeaux; Sherene Loi; Leora Horn; Melinda E Sanders; P Brent Ferrell; Yaomin Xu; Jeffrey A Sosman; Randall S Davis; Justin M Balko
Journal:  JCI Insight       Date:  2018-12-20

2.  Chediak-Higashi syndrome: Lysosomal trafficking regulator domains regulate exocytosis of lytic granules but not cytokine secretion by natural killer cells.

Authors:  Aleksandra Gil-Krzewska; Stephanie M Wood; Yousuke Murakami; Victoria Nguyen; Samuel C C Chiang; Andrew R Cullinane; Giovanna Peruzzi; William A Gahl; John E Coligan; Wendy J Introne; Yenan T Bryceson; Konrad Krzewski
Journal:  J Allergy Clin Immunol       Date:  2015-10-21       Impact factor: 10.793

3.  The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response.

Authors:  Bala Ramaswami; Iulia Popescu; Camila Macedo; Chunqing Luo; Ron Shapiro; Diana Metes; Geetha Chalasani; Parmjeet S Randhawa
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

Review 4.  Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity.

Authors:  Stefan Kiesgen; John C Messinger; Navin K Chintala; Zachary Tano; Prasad S Adusumilli
Journal:  Nat Protoc       Date:  2021-02-15       Impact factor: 13.491

5.  Cancer immunotherapy with interleukin-2-activated natural killer cells.

Authors:  Per H Basse; Theresa L Whiteside; Ronald B Herberman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.860

6.  "Ninjinto" (Ginseng Decoction), a Traditional Japanese Herbal Medicine, Improves Gastrointestinal Symptoms and Immune Competence in Patients with Chronic Intestinal Failure.

Authors:  Shuichiro Uehara; Keiko Ogawa; Junsuke Arimitsu; Hiroomi Okuyama
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-01       Impact factor: 2.629

7.  Effect of type of TAG fatty acids on lutein and zeaxanthin bioavailability.

Authors:  Béatrice Gleize; Franck Tourniaire; Laurence Depezay; Romain Bott; Marion Nowicki; Lionel Albino; Denis Lairon; Emmanuelle Kesse-Guyot; Pilar Galan; Serge Hercberg; Patrick Borel
Journal:  Br J Nutr       Date:  2012-12-11       Impact factor: 3.718

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.